Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar Reimbursement Under The Sequester: The Lower The Price, The Bigger The Spread

This article was originally published in RPM Report

Executive Summary

Novartis has become the first company to announce a biosimilar application in the US, and will likely become the first company to test the Medicare reimbursement formula for the new product class. The 2% sequester cut in Medicare may actually make that formula more attractive for biosimilars than the original law. Here’s how.


Related Content

Reimbursement of Biosimilar and Biosimilar-similar ESAs





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts